Clinicians weigh ketamine vs FDA-approved esketamine for TRD, with evolving guidance on dosing, safety monitoring, and long-term maintenance decisions.
Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.